时间标签：数据日期 2026-10-31 · 生成时间 2026-11-01 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/28–2026/10/31 ｜ 情报发生日期 2026-10-31
研究问题
However, global epidemiological registries reveal a profound shift: while childhood varicella-preventative immunization programs have reduced pediatric varicella incidence, the absolute morbidity and healthcare burden of herpes zoster and its severe neurological sequelae (such as postherpetic neuralgia and vasculopathy) are rising sharply in populations aged over 50 years (–).
方法
Traditional clinical paradigms have long simplified VZV infection into a strict biphasic event: primary infection causing childhood varicella followed by ganglionic latency and subsequent reactivation as herpes zoster (HZ) upon declining host immunity (, ).；Natural experiments and propensity-score-matched cohort studies show that older adults receiving the live-attenuated zoster vaccine (ZVL) exhibit an approximate 20% relative reduction in incident dementia diagnoses ().；Strikingly, cohorts immunized with the respiratory syncytial virus (RSV) vaccine, which utilizes the dose-sparing AS01E liposomal formulation (, ) from the same AS01 adjuvant family, demonstrated a comparable 29% reduction in dementia risk ().
核心结论
However, global epidemiological registries reveal a profound shift: while childhood varicella-preventative immunization programs have reduced pediatric varicella incidence, the absolute morbidity and healthcare burden of herpes zoster and its severe neurological sequelae (such as postherpetic neuralgia and vasculopathy) are rising sharply in populations aged over 50 years (–).；Conversely, clinical and translational evidence links subclinical or recurrent VZV reactivation to chronic degenerative and cerebrovascular conditions, including Alzheimer’s disease (AD) and cerebral amyloid angiopathy (CAA) (, ).；Furthermore, the transition to the recombinant vaccine (RZV) is associated with a 17% increase in dementia-free survival time (translating to 164 additional days lived without a diagnosis) compared to ZVL (). ‖ 结论：The trail is essential to prospectively confirm vaccine-mediated neuroprotection and guide its integration into preventative geriatric clinical frameworks.
局限
Emerging analyses indicate that VZV is not merely a superficial dermatological pathogen causing self-limiting vesicular eruptions; rather, it represents a chronic systemic burden that drives persistent immuno-metabolic exhaustion ().；As a paradigm of neurodegenerative disorders, Alzheimer’s disease (AD) is supported by a growing body of reported data that warrant exploring the correlation between varicella-zoster virus (VZV) infection-induced neuroinflammation and AD risk.
对本项目的价值
★☆☆☆☆ 脑老化是最大未满足需求，也是终点最难量化的领域；biomarker 与认知读数选择最敏感。
全文来源
PMC JATS 全文（正文 28,117 字符，已过标题/DOI 逐字归属校验）
原文题录
- 英文标题：VZV reactivation, immune remodeling, and dementia risk.
- 期刊与标识：Front Immunol · PMID 42953047 · DOI 10.3389/fimmu.2026.1953013
A 级证据分级：A 级（同行评议人体研究）
本文属人体研究证据，但需注意：观察性或小样本干预的结论不等于已证实临床获益；效应量与长期安全性仍需更大规模、更长随访的试验验证。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」撰写，依据已获取的期刊全文（方法、样本量与结论已回到原文核对）；未能获取全文的同批条目另行标注「摘要级」，全程未做任何数值推算补全。